
Recurrence‐free survival after liver transplantation for small hepatocellular carcinoma
Author(s) -
Bechstein W. O.,
Guckelberger O.,
Kling N.,
Rayes N.,
Tullius S. G.,
Lobeck H.,
Vogl T.,
Jonas S.,
Neuhaus P.
Publication year - 1998
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/j.1432-2277.1998.tb01111.x
Subject(s) - medicine , hepatocellular carcinoma , liver transplantation , stage (stratigraphy) , orthotopic liver transplantation , milan criteria , gastroenterology , carcinoma , transplantation , overall survival , surgery , oncology , paleontology , biology
Recurrence‐free survival (RFS) in patients with small hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT) was analyzed. From 1988 until 1996, 725 OLTs were performed in 669 patients. In 52 adults, HCC was confirmed histologically. OLT was limited to patients with small (<5 cm) HCC with a maximum number of three nodules. Actuarial survival for these 52 patients at 1 and 5 years is 88% and 71%. RFS was defined as time until death without recurrence, time until follow up with a diagnosis of recurrence, or, in patients without recurrence, time of last follow up. Overall, the 5‐year RFS was 60%. Five‐year RFS was less for bilobar compared to unilobar tumors (36% vs 70%), less for stage IVa tumors (UICC) compared to stage I‐III tumors (17% vs 71%), and less for multiple compared to solitary tumors (54% vs 67%). In conclusion, potential cure may be achieved in more than 50% of all transplanted patients.